Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.

Current treatments for age-related macular degeneration (AMD) are limited to the later form of the disease. Both complications and high costs should be expected with outpatient surgery.

Macular degeneration is a devastating eye condition that affects around 200 million people worldwide, primarily those over ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ... for ...

photodynamic therapy with verteporfin and surgical treatments. Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration ...

Alcon will continue the development of POT-4 for the potential treatment of both wet and dry AMD. Modulation of the complement system — a key component of innate immunity that detects foreign or ...